KR102278760B1 - 방사선과 조합하여 사용하는 할로겐- 및 디아미노-를 포함하는 방사선 증감제 화합물 - Google Patents

방사선과 조합하여 사용하는 할로겐- 및 디아미노-를 포함하는 방사선 증감제 화합물 Download PDF

Info

Publication number
KR102278760B1
KR102278760B1 KR1020157019682A KR20157019682A KR102278760B1 KR 102278760 B1 KR102278760 B1 KR 102278760B1 KR 1020157019682 A KR1020157019682 A KR 1020157019682A KR 20157019682 A KR20157019682 A KR 20157019682A KR 102278760 B1 KR102278760 B1 KR 102278760B1
Authority
KR
South Korea
Prior art keywords
cancer
delete delete
radiation
compound
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157019682A
Other languages
English (en)
Korean (ko)
Other versions
KR20150120953A (ko
Inventor
큉-빈 루
Original Assignee
큉-빈 루
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 큉-빈 루 filed Critical 큉-빈 루
Publication of KR20150120953A publication Critical patent/KR20150120953A/ko
Application granted granted Critical
Publication of KR102278760B1 publication Critical patent/KR102278760B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
    • C07C211/52—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020157019682A 2012-12-20 2013-12-20 방사선과 조합하여 사용하는 할로겐- 및 디아미노-를 포함하는 방사선 증감제 화합물 Expired - Fee Related KR102278760B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261797983P 2012-12-20 2012-12-20
US61/797,983 2012-12-20
PCT/CA2013/051005 WO2014094178A1 (en) 2012-12-20 2013-12-20 Radiosensitizer compounds for use in combination with radiation

Publications (2)

Publication Number Publication Date
KR20150120953A KR20150120953A (ko) 2015-10-28
KR102278760B1 true KR102278760B1 (ko) 2021-07-20

Family

ID=50977492

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157019682A Expired - Fee Related KR102278760B1 (ko) 2012-12-20 2013-12-20 방사선과 조합하여 사용하는 할로겐- 및 디아미노-를 포함하는 방사선 증감제 화합물

Country Status (10)

Country Link
US (1) US9655965B2 (enExample)
EP (1) EP2935215B1 (enExample)
JP (1) JP6321673B2 (enExample)
KR (1) KR102278760B1 (enExample)
CN (1) CN105164107B (enExample)
AU (1) AU2013362757B2 (enExample)
BR (1) BR112015014855A2 (enExample)
CA (1) CA2895526C (enExample)
MX (1) MX2015008010A (enExample)
WO (1) WO2014094178A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114380700A (zh) * 2013-10-08 2022-04-22 卢庆彬 用于靶向化疗的非铂基抗癌化合物
PL3277284T3 (pl) * 2015-04-02 2021-03-08 Proximagen, Llc Nowe terapie nowotworu
CN106045932B (zh) * 2016-06-06 2018-05-15 浙江省肿瘤医院 一种具有放射增敏作用的化合物及其应用
JP6955243B2 (ja) * 2017-02-24 2021-10-27 学校法人北里研究所 ネクローシスの検出キット及びその使用
EP3804719A4 (en) * 2018-05-30 2022-03-30 Pharos Ibio Co., Ltd. Use of 2,3,5-substituted thiophene compound for enhancement of radiotherapy
WO2021224186A1 (en) * 2020-05-04 2021-11-11 Institut Curie New pyridine derivatives as radiosensitizers
CN114478524A (zh) * 2022-03-15 2022-05-13 江苏省肿瘤医院 1,8-萘啶类化合物及其应用
CN114560799A (zh) * 2022-03-15 2022-05-31 江苏省肿瘤医院 腈基取代苯基类化合物及其应用
CN120501862B (zh) * 2025-07-18 2025-10-10 四川大学华西医院 一种能够放射增敏和防护放射性损伤的双效化合物、包含其的组合物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006067466A2 (en) 2004-12-22 2006-06-29 The Wellcome Trust Limited Pyrazines and pyridines and derivatives thereof as therapeutic compounds
WO2008082487A2 (en) 2006-12-20 2008-07-10 Schering Corporation Novel jnk inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5011451B1 (enExample) * 1969-05-05 1975-05-01
GB1363735A (en) * 1970-10-23 1974-08-14 Hoechst Ag Process for the manufacture of benzimidazolones
US3822261A (en) * 1972-10-30 1974-07-02 Dow Chemical Co 5,6-dihalo-2-fluoroalkyl-1h-imidazo(4,5-b)pyrazines
GR72941B (enExample) * 1978-10-20 1984-01-16 Lilly Co Eli
US4210647A (en) * 1979-06-18 1980-07-01 Eli Lilly And Company Antiviral combinations
JPS597175A (ja) * 1982-07-01 1984-01-14 メルク・エンド・カムパニ−・インコ−ポレ−テツド 放射線治療用添加剤として有用な、クロロニトロアミノピラジン及びアルキルアミノピラジンのアミノとアミド誘導体
GB8722488D0 (en) * 1987-09-24 1987-10-28 Fujisawa Pharmaceutical Co Imidazopyridine compound
CA2138026C (en) * 1992-06-22 2003-09-09 Eckard Weber Novel 1,4-dihydroquinoxaline-2,3-diones and uses therefor as glycine receptor antagonists
EP0743855A1 (en) * 1994-01-03 1996-11-27 Acea Pharmaceuticals, Inc. 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor
US5753687A (en) * 1995-06-19 1998-05-19 Ontogen Corporation Modulators of proteins with phosphotryrosine recognition units
CA2397665A1 (en) * 2000-01-24 2001-07-26 Merck & Co., Inc. Alpha v integrin receptor antagonists
US6538010B1 (en) * 2000-11-08 2003-03-25 Research Triangle Institute Compounds and methods for promoting smoking cessation
US20090137640A1 (en) * 2005-04-01 2009-05-28 Taiho Pharmaceutical Co.Ltd Potentiator for radiation therapy comprising pyridine derivative as active ingredient
CN101155782B (zh) * 2005-04-01 2011-05-04 大鹏药品工业株式会社 以吡啶衍生物为有效成分的放射线治疗增强剂
JP2010500372A (ja) * 2006-08-09 2010-01-07 スミスクライン ビーチャム コーポレーション オピオイド受容体に対するアンタゴニストまたはインバースアゴニストとしての新規化合物
US8088767B2 (en) * 2006-09-28 2012-01-03 Exelixis, Inc. JAK-2 modulators and methods of use
WO2010054398A1 (en) * 2008-11-10 2010-05-14 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US20120156311A1 (en) * 2009-09-01 2012-06-21 Lu qing-bin Combination therapy for cancer comprising a platinum-based antineoplastic agent and a biocompatible electron donor
US8962631B2 (en) * 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
GB201017345D0 (en) * 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006067466A2 (en) 2004-12-22 2006-06-29 The Wellcome Trust Limited Pyrazines and pyridines and derivatives thereof as therapeutic compounds
WO2008082487A2 (en) 2006-12-20 2008-07-10 Schering Corporation Novel jnk inhibitors

Also Published As

Publication number Publication date
CN105164107A (zh) 2015-12-16
US20150343059A1 (en) 2015-12-03
CN105164107B (zh) 2017-12-05
EP2935215A1 (en) 2015-10-28
EP2935215B1 (en) 2019-11-13
MX2015008010A (es) 2016-04-26
JP2016504325A (ja) 2016-02-12
CA2895526C (en) 2021-08-24
BR112015014855A2 (pt) 2017-07-11
US9655965B2 (en) 2017-05-23
CA2895526A1 (en) 2014-06-26
KR20150120953A (ko) 2015-10-28
JP6321673B2 (ja) 2018-05-09
EP2935215A4 (en) 2016-10-26
WO2014094178A1 (en) 2014-06-26
AU2013362757B2 (en) 2018-06-14
AU2013362757A1 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
KR102278760B1 (ko) 방사선과 조합하여 사용하는 할로겐- 및 디아미노-를 포함하는 방사선 증감제 화합물
JP5596924B2 (ja) ビンカアルカロイドｎ酸化物および類似体による過剰増殖疾患の処置
JP6765302B2 (ja) 標的化化学療法に使用するための非白金ベースの抗がん化合物
WO2008033440A2 (en) Treatment of hyperproliferative diseases with anthraquinones
KR20220008869A (ko) 항암 핵 호르몬 수용체-표적화 화합물
US11286271B2 (en) Iridium (III) complexes containing N-heterocyclic carbene ligand, synthesis, and their use thereof in cancer treatment
JP6170147B2 (ja) 癌治療
RU2381799C2 (ru) Лечение пролиферативных заболеваний производными эпотилона и излучением
CA2598249A1 (en) Treatment of hyperproliferative diseases with anthraquinones

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240714

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240714